Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch.
The negotiations, which begin Thursday, could meet fierce opposition from drugmakers, experts say. The final negotiated prices will go into effect in 2026.
Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for what are expected to be significant discounts on 10 of its high-cost medicines, an important step in the Medicare health program's first ever price negotiations.
Starting April 1, state employees in North Carolina will no longer have insurance coverage for costly weight-loss medications like Wegovy and Zepbound.